Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19753569 | 0.84 | CA2 (0.60) | CA2CA1CA12CA3AR | |
| SCHEMBL24640985 | 0.84 | CA2 (0.60) | CA2CA1CA12CA3AR | |
| SCHEMBL9207998 | 0.81 | CA2 (0.60) | CA2CA1CA12CA3AR | |
| SCHEMBL7547216 | 0.80 | CA2 (0.37) | CA2CA1CA12CA3AR | |
| SCHEMBL9214420 | 0.80 | CA2 (0.57) | CA2CA1CA12CA3AR | |
| Hydrochloric Acid SCHEMBL10796323 | 0.79 | CA2 (0.63) | CA2CA1CA12CA3AR | |
| SCHEMBL9212312 | 0.79 | CA2 (0.56) | CA2CA1CA12CA3AR | |
| SCHEMBL6093540 | 0.76 | CA2 (0.74) | CA2CA1CA12CA3AR | |
| SCHEMBL3646869 | 0.76 | CA2 (0.74) | CA2CA1CA12CA3AR | |
| SCHEMBL10514631 | 0.73 | CA2 (0.70) | CA2CA1CA12CA3AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813618-B1 | METHOD OF OBTAINING DERIVATIVES OF 4-(N-ALKYLAMINE)-5,6-DIHYDRO-4H-THIENO-[2,3-B]-THIOPYRAN | CRYSTAL PHARMA SAU (ES) | 2013-07-03 | — | — | EP | disclosed |
| US-7030250-B2 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | RAGATIVES, S.L. (ES) | 2006-04-18 | — | — | US | disclosed |
| EP-1329453-B1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFONAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | RAGACTIVES SL (ES) | 2004-06-16 | — | — | EP | disclosed |
| US-20030220509-A1 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | RAGACTIVES, S.L. | 2003-11-27 | — | — | US | disclosed |
| EP-1329453-A1 | METHOD FOR OBTAINING 4-(N-ALKYLAMINE)-5, 6-DIHYDRO-4H-THIENO-(2,3-B)-THIOPYRAN-2-SULFAMIDE-7, 7-DIOXIDES AND INTERMEDIATE PRODUCTS | Ragactives, S.L. (ES) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220509-A1 | Process for obtaining 4-(N-alkylamino)-5,6-dihydro-4H-thien-(2,3-b)-thiopyran-2-sulfonamide-7,7-dioxides and intermediates | CA7, CA2, CA4 | CA2 2/4885CA1 24/4885CA12 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.